ABSENCE OF PHARMACOKINETIC INTERACTION OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B‐CELL NON‐HODGKIN'S LYMPHOMA (INHL)Andres Forero‐Torres, Sumit Madan, Jason C. Chandler et al.|Hematological Oncology|2017Cited by 0
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's LymphomaAndres Forero‐Torres, Sumit Madan, Michelle Quinlan et al.|Clinical Pharmacology in Drug Development|2022Cited by 0